Navigation Links
Catalent to Launch OneBio Suite for Integrated Biologics Development, Manufacturing and Supply at BIO International 2019
Date:5/23/2019

Catalent (Booth 3101), the leading global provider of advanced delivery technologies and development solutions for drugs, biologics and consumer health products, is to launch its new OneBio SuiteSM for the integrated development, manufacturing, and clinical supply of biologic drugs at the BIO International Convention, which takes place at the Pennsylvania Convention Center in Philadelphia, from June 3-6, 2019.

OneBio has been designed specifically to address the challenges facing biologic development companies that are looking to accelerate programs to clinic or market, or that require greater simplicity in the development process, including fewer internal resource needs and a reduced risk of rework. As a single, integrated provider, Catalent Biologics’ OneBio Suite will aim to reduce timelines, risk and complexity by providing customers with a single contract, program manager, and development timeline from cell line to clinical supply with harmonized quality systems. The OneBio Suite draws upon Catalent’s proven track record of progressing biologic drugs to market, which includes over 115 global clinical trials and 11 commercially marketed monoclonal antibodies using the company’s GPEx® cell line development technology, and 20 approved products through fill/finish and commercial supply to global markets.

“Time is often lost for sponsors on the path to clinic from contract negotiation, site inspections, handoffs, and poor communication between multiple vendors,” commented Bernie Clark, Vice President, Marketing & Strategy, Catalent Biologics & Specialty Drug Delivery. “Through our new OneBio Suite, Catalent is uniquely positioned to provide an integrated offering that can accelerate biologic development potentially shaving weeks to months off standard timelines and allowing our customers to get to clinic and market faster.”

Additionally, at the BIO Convention, Steven Hager, Ph.D., Senior Director, Technical Support, will present ‘Cell Line Development Strategies for Difficult to Express Proteins’ as part of the ‘Emerging Techniques, Technologies and Strategies’ track. His presentation takes place on Wednesday, June 5 from 11:40 a.m.-12:00 p.m. at the BPI Theater, Booth #3211 in the BioProcess Zone.

On the same day, from 1:45-2:30 p.m., Dr. Hager will also participate in a ‘Single Use Systems Versus Stainless Steel’ roundtable, also at the BPI Theater.

Catalent Biologics provides advanced technologies and integrated solutions for biologic and biosimilar development and manufacturing, from DNA to fill/finish and commercial supply, through its extensive Biologics network including: Bloomington, Indiana, where the company recently announced a twentieth commercial launch of a fill/finish product, and; Madison, Wisconsin, home of Catalent Biologics’ proprietary GPEx technology for stable, high-yielding mammalian cell lines with eleven approved molecules. For more information on Catalent Biologics, visit biologics.catalent.com.

Notes for Editors
About Catalent Biologics
Catalent Biologics has 20+ years’ experience in development, manufacturing, and analytical services for new biological entities, biosimilars, and antibody-drug conjugates. Catalent has worked with 600+ mAbs and 80+ proteins, and more than 115 clinical trials and 11 marketed products have used GPEx® cell line engineering technology. A further 20 commercially-approved products have employed Catalent Biologics’ capabilities through to aseptic fill/finish. Using advanced protein improvement technology and tailored solutions from DNA through to clinical and commercial supply, Catalent Biologics brings better biologic treatments to patients, faster. For more information, visit biologics.catalent.com.

About Catalent
Catalent is the leading global provider of advanced delivery technologies and development solutions for drugs, biologics and consumer health products. With over 85 years serving the industry, Catalent has proven expertise in bringing more customer products to market faster, enhancing product performance and ensuring reliable clinical and commercial product supply. Catalent employs over 11,000 people, including over 1,800 scientists, at more than 30 facilities across five continents, and in fiscal year 2018 generated approximately $2.5 billion in annual revenue. Catalent is headquartered in Somerset, New Jersey. For more information, visit http://www.catalent.com.

More products. Better treatments. Reliably supplied.™

Read the full story at https://www.prweb.com/releases/catalent_to_launch_onebio_suite_for_integrated_biologics_development_manufacturing_and_supply_at_bio_international_2019/prweb16333539.htm.


'/>"/>
Source: PRWeb
Copyright©2019 Vocus, Inc.
All rights reserved


Related biology news :

1. Planning for Orphan Drug Supply to be Discussed by Catalent at World Orphan Drug Congress
2. Catalent Receives P&G External Business Partner of the Year Award
3. Zer0 to 5ive Turns 20; Celebrates with Launch of New Startup Package
4. ASGCT Launches Clinical Trials Finder on Clinical Trials Day 2019
5. Akadeum Launches Seven New Products at Immunology 2019 Conference in San Diego
6. FISO Technologies Launches the FOP-M200, the Smallest Commercially Available Pressure Transducer
7. Medpricer Adds Rich Data Extraction to Portfolio of Services with Launch of mSource® AI Contract Text Analysis
8. Swiss Biotech Gnubiotics, Announces Global Launch of GNU100 the First Microbiome Specialty Ingredient for Companion Animal Gut Health
9. SeqOnce Biosciences Launches RhinoSeq™ Rapid DNA Library Preparation Kit
10. FileWave Launches New Channel Partner Program
11. FEITIAN Technologies Launches Two New Payment Card Solutions
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/9/2019)... ... July 09, 2019 , ... Murrieta Genomics, a launch pad ... The founder and CEO of Tx Genetic, Helen Harrison, has spent several years ... epithelial connective tissue disorders. , “We are pleased and excited to join the ...
(Date:7/5/2019)... , ... July 05, 2019 , ... ... to bring its patented Tractus™ Platform to governments around the world. , ... edge technology and point of care solutions to operating theatres worldwide to address ...
(Date:6/24/2019)... ... 24, 2019 , ... According to the World Health Organization , over ... STDs: chlamydia, gonorrhea, trichomoniasis (or "trich") and syphilis. And that’s not counting HIV. ... men accounted for the largest number of HIV diagnoses (9,807), followed by Hispanic/Latino men ...
Breaking Biology News(10 mins):
(Date:6/26/2019)... (PRWEB) , ... June 26, 2019 , ... Alice Branton ... treatment on improving physicochemical properties of Magnesium Gluconate, which can prove to be beneficial ... 125% alteration of characteristic differentiation peak, change in crystallite size , Over ...
(Date:6/18/2019)... ... ... Personalized Stem Cells, Inc (“PSC”), a human adipose-derived stem cell company, ... a person’s own adipose-derived stem cells to treat their osteoarthritis. The first clinical trial ... is the first of several planned clinical trials which will enable qualified PSC-enrolled physicians ...
(Date:6/11/2019)... ... June 10, 2019 , ... Thought Technology Ltd ... appointment of Biofeedback Tech Ltd as its authorised distributor for the ... of many therapeutic treatments and clinical assessment protocols to treat stress related disorders ...
(Date:6/11/2019)... ... June 10, 2019 , ... ... will add 80 of its scientific journals to DeepDyve’s rental service for peer-reviewed ... DeepDyve’s continually expanding library of more than 20 million articles, sourced from more ...
Breaking Biology Technology: